Standardized templates for the benefit-risk assessment of COVID-19 vaccine candidates endorsed by WHO Global Advisory Committee on Vaccine Safety (GACVS)

Dr Sonali Kochhar led the development of standardized templates with key considerations for the benefit-risk assessment of COVID-19 vaccine candidates has been led by. The templates have been developed for all the platforms being utilized for COVID-19 vaccines (including nucleic acid (RNA and DNA), protein, inactivated viral and live attenuated viral vaccines) and been published (The templates have been developed for the all the platforms being utilized for COVID-19 vaccines (including nucleic acid (RNA and DNA), protein, inactivated viral and live attenuated viral vaccines) and been published in Vaccine. (https://www.sciencedirect.com/science/article/pii/S0264410X20308306?via%3Dihub; https://www.sciencedirect.com/science/article/pii/S0264410X20309440?via%3Dihub; https://www.sciencedirect.com/science/article/pii/S0264410X20307891?via%3Dihub; https://www.sciencedirect.com/science/article/pii/S0264410X20310306, https://brightoncollaboration.us/bravato/).

The templates have been endorsed by the WHO Global Advisory Committee on Vaccine Safety (GACVS) and are being utilized by COVID-19 vaccine developers, including Pharmaceutical and CEPI funded vaccine developers, to evaluate and communicate the benefit-risk of COVID-19 vaccine candidates.